Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2022-06-22 AGM Information
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Uchwała Zwyczajnego Walnego Zgromadzenia Spółki w sprawie w sprawie pokrycia straty oraz wypłaty dywidendy za rok obrotowy 2021 - Content (PL)
AGM Information Classification · 99% confidence The document text, written in Polish, explicitly discusses resolutions passed by the Ordinary General Meeting (ZWZ) on June 22, 2022, regarding the coverage of the net loss for the 2021 fiscal year and the payment of a dividend. Specifically, it states the dividend amount (0.29 PLN per share), the total amount (14,798,700.00 PLN), the record date (July 1, 2022), and the payment date (July 11, 2022). This content directly corresponds to the definition of 'Notice of Dividend Amount' (DIV). Although it mentions the AGM (ZWZ), the core subject is the dividend declaration, not general AGM materials or voting results.
2022-06-22 Polish
Informacja na temat statusu wniosku o przyznanie statusu Breakthrough Designation dla Falkieri (esketaminy Celon DPI) w leczeniu depresji lekoopornej dwubiegunowej przez FDA - Content (PL)
Regulatory Filings Classification · 100% confidence The document is a formal communication from a company (Celon Pharma S.A.) informing the public about a specific regulatory action taken by the FDA regarding a drug application (Breakthrough Designation for Falkieri). It details the rejection of the application and the reasons provided by the FDA, along with the company's next steps (consultations). This type of communication, reporting on significant legal, regulatory, or legal proceedings involving the company, fits best under the Legal Proceedings Report (LTR) category, as it concerns a formal interaction and outcome with a regulatory body (FDA) regarding product development status. It is not an earnings release, an annual report, or a general regulatory filing (RNS), but a specific update on a regulatory/legal matter.
2022-06-20 Polish
Sprawozdanie RN za 2021 r.
Board/Management Information Classification · 99% confidence The document is titled "Sprawozdanie Rady Nadzorczej Celon Pharma S.A. za rok obrotowy 2021 uwzględniające wymogi Dobrych Praktyk Spółek Notowanych na GPW 2021" (Report of the Supervisory Board of Celon Pharma S.A. for the financial year 2021, including the requirements of the Good Practices for Companies Listed on the WSE 2021). It details the composition of the Supervisory Board, its activities, the Audit Committee's work, an assessment of the company's situation, internal controls, and provides an opinion on the Financial Statement for 2021 and the Management Board's proposal regarding the dividend. This content strongly aligns with the requirements for a comprehensive annual review and governance report prepared by the Supervisory Board, which falls under the scope of Governance Information (CGR) or potentially a component of the Annual Report (10-K), but given its specific focus on the Supervisory Board's oversight and opinion on the annual accounts and governance practices, CGR is a strong fit, although it is a detailed annual report component. Since it is a formal report covering governance, internal controls, and opinion on the annual financial statements for the full year 2021, it is best classified as Governance Information (CGR) as it focuses heavily on the oversight structure and compliance with corporate governance codes, which is distinct from the full 10-K filing itself, but more specific than a general Audit Report (AR). However, in many jurisdictions, the Supervisory Board's report on the annual accounts and governance is a mandatory part of the Annual Report package. Given the depth of financial review (balance sheet figures, P&L loss, dividend recommendation) and the explicit reference to the financial year 2021, it functions as a key component of the annual reporting cycle. Comparing CGR (Governance Information) and 10-K (Annual Report): This document is essentially the Supervisory Board's section of the annual report, heavily focused on governance and oversight. If a dedicated 10-K is not present, this detailed annual review often substitutes or is the primary document. Since it covers the entire financial year and includes opinions on the financial statements, it is most accurately classified as a comprehensive annual review document. Given the options, and its focus on governance and annual review, CGR is the most precise fit for a document detailing governance structure and oversight opinion, even though it touches upon the financial results.
2022-06-15 Polish
Sprawozanie o wynagrodzeniach za 2021
Remuneration Information Classification · 100% confidence The document title is "SPRAWOZDANIE O WYNAGRODZENIACH CZŁONKÓW ZARZĄDU I RADY NADZORCZEJ CELON PHARMA S.A. ZA OKRES 01.01.2021.- 31.12.2021." which translates to "REPORT ON REMUNERATION OF MANAGEMENT BOARD AND SUPERVISORY BOARD MEMBERS OF CELON PHARMA S.A. FOR THE PERIOD 01.01.2021-31.12.2021.". The content details the structure, conditions, and amounts of remuneration paid to board members and supervisory board members for the specified fiscal year. This directly corresponds to the definition of Remuneration Information, which is mapped to the code DEF 14A (Proxy Solicitation & Information Statement, often used for compensation disclosure in US context, but here matching the specific content type description). Reviewing the provided definitions: - 'DEF 14A' is defined as: "Report detailing compensation for top executives and directors." - This document is explicitly a detailed report on executive and director compensation. Therefore, the classification is DEF 14A.
2022-06-15 Polish
Raport z oceny Sprawozdania o wynagrodzeniach
Audit Report / Information Classification · 98% confidence The document is titled "Raport atestacyjny" (Attestation Report) and specifically references a "Raport niezależnego biegłego rewidenta z usługi atestacyjnej obejmującej ocenę 'Sprawozdania o wynagrodzeniach Członków Zarządu i Rady Nadzorczej Celon Pharma S.A. za okres 01.01.2021-31.12.2021'" (Report of the independent auditor from the assurance service covering the assessment of the 'Report on remuneration of the Management Board and Supervisory Board Members of Celon Pharma S.A. for the period 01.01.2021-31.12.2021'). This document is an independent audit/assurance report concerning the remuneration report. This aligns best with the 'Audit Report / Information' category (AR), which covers standalone audit reports and applied accounting principles, distinguishing it from the full Annual Report (10-K) or the Remuneration Information itself (DEF 14A). FY 2021
2022-06-15 Polish
Uzupełnienie dokumentacji na Zwyczajne Walne Zgromadzenie Celon Pharma S.A. zwołane na dzień 22 czerwca 2022 r. - Content (PL)
AGM Information Classification · 95% confidence The document is a follow-up announcement (uzupełnieniu raportu bieżącego) regarding the upcoming Annual General Meeting (Zwyczajnego Walnego Zgromadzenia) scheduled for June 22, 2022. The management is providing attachments that will be presented at the AGM. Specifically, it attaches the Supervisory Board's Report for 2021 and the Remuneration Report for the Management and Supervisory Board for 2021. Since the document's primary function is to announce the availability of materials intended for the AGM (including the remuneration report and board report), and given its short length (953 chars), it fits the description of an announcement regarding meeting materials rather than the full reports themselves. However, the content explicitly mentions the 'Sprawozdanie o wynagrodzeniach' (Remuneration Report), which maps directly to DEF 14A, and the overall context is tied to the AGM. Since it is an announcement *attaching* the remuneration report and the board report for the AGM, it is most closely related to the AGM process or the specific reports being attached. Given the explicit mention of the remuneration report ('Sprawozdanie o wynagrodzeniach'), DEF 14A is a strong candidate, but since it is an announcement *about* the AGM materials, AGM-R (AGM Information) is also relevant. Because the document is short and explicitly states it is 'przekazuje w załączeniu' (attaching) specific reports for the upcoming AGM, it functions as an announcement related to the AGM proceedings. I will classify it as AGM-R as it directly relates to materials presented at the AGM.
2022-06-15 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.